Natera Inc (NTRA)vsTenet Healthcare Corporation (THC)

NTRA

Natera Inc

NASDAQ

$194.24

-11.64%

HEALTHCARE · Cap: $30.71B

THC

Tenet Healthcare Corporation

NYSE

$190.38

-1.93%

HEALTHCARE · Cap: $16.72B

⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Tenet Healthcare Corporation generates 830% more annual revenue ($21.45B vs $2.31B). THC leads profitability with a 7.9% profit margin vs -9.0%. THC earns a higher WallStSmart Score of 66/100 (B-).

NTRA

Avoid

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 6.5

Piotroski: 4/9

THC

Strong Buy

out of 100

Grade: B-

Growth: 6.0Profit: 7.0Value: 7.3Quality: 6.3

Piotroski: 6/9Altman Z: 1.69

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for NTRA.

THCUndervalued (+78.8%)

Margin of Safety

+78.8%

Fair Value

$1068.55

Current Price

$190.38

$878.17 discount

UndervaluedFair: $1068.55Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NTRA1 strengths · Avg: 10.0/10

Revenue GrowthGrowth

39.8%10/10

Revenue surging 39.8% year-over-year

THC4 strengths · Avg: 9.5/10

P/E RatioValuation

10.1x10/10

Attractively priced relative to earnings

Return on EquityProfitability

30.3%10/10

Every $100 of equity generates 30 in profit

EPS GrowthGrowth

87.6%10/10

Earnings expanding 87.6% YoY

Free Cash FlowQuality

$1.46B8/10

Generating 1.5B in free cash flow

Areas to Watch

NTRA4 concerns · Avg: 2.8/10

Price/BookValuation

15.8x4/10

Trading at 15.8x book value

EPS GrowthGrowth

0.0%4/10

0.0% earnings growth

Return on EquityProfitability

-14.3%2/10

ROE of -14.3% — below average capital efficiency

Profit MarginProfitability

-9.0%1/10

Currently unprofitable

THC4 concerns · Avg: 3.3/10

Revenue GrowthGrowth

2.8%4/10

2.8% revenue growth

Altman Z-ScoreHealth

1.694/10

Distress zone — elevated risk

Profit MarginProfitability

7.9%3/10

7.9% margin — thin

PEG RatioValuation

4.802/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : NTRA

The strongest argument for NTRA centers on Revenue Growth. Revenue growth of 39.8% demonstrates continued momentum.

Bull Case : THC

The strongest argument for THC centers on P/E Ratio, Return on Equity, EPS Growth.

Bear Case : NTRA

The primary concerns for NTRA are Price/Book, EPS Growth, Return on Equity.

Bear Case : THC

The primary concerns for THC are Revenue Growth, Altman Z-Score, Profit Margin.

Key Dynamics to Monitor

NTRA profiles as a hypergrowth stock while THC is a value play — different risk/reward profiles.

NTRA carries more volatility with a beta of 1.57 — expect wider price swings.

NTRA is growing revenue faster at 39.8% — sustainability is the question.

THC generates stronger free cash flow (1.5B), providing more financial flexibility.

Bottom Line

THC scores higher overall (66/100 vs 31/100). Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Natera Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.

Tenet Healthcare Corporation

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Tenet Healthcare Corporation is a diversified health services company. The company is headquartered in Dallas, Texas.

Compare with Other DIAGNOSTICS & RESEARCH Stocks

NTRA vs TMO NTRA vs DHR NTRA vs IDXX NTRA vs WAT NTRA vs A THC vs TMO THC vs DHR THC vs IDXX THC vs WAT THC vs A

Want to dig deeper into these stocks?

Full NTRA Analysis →Full THC Analysis →